These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 6321689)

  • 1. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study.
    Valdivieso M; Burgess MA; Ewer MS; Mackay B; Wallace S; Benjamin RS; Ali MK; Bodey GP; Freireich EJ
    J Clin Oncol; 1984 Mar; 2(3):207-14. PubMed ID: 6321689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer.
    Umsawasdi T; Valdivieso M; Booser DJ; Barkley HT; Ewer M; MacKay B; Dhingra HM; Murphy WK; Spitzer G; Chiuten DF
    Cancer; 1989 Nov; 64(10):1995-2000. PubMed ID: 2553235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
    J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Random prospective study cyclophosphamide, doxorubicin, and methotrexate (CAM) combination chemotherapy versus single-agent sequential chemotherapy in non small cell lung cancer.
    Einhorn LH; Williams SD; Stevens EE; Bond WH; Chenoweth L
    Cancer Treat Rep; 1982 Dec; 66(12):2005-11. PubMed ID: 6291763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
    J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.
    Souhami RL; Rudd R; Ruiz de Elvira MC; James L; Gower N; Harper PG; Tobias JS; Partridge MR; Davison AG; Trask C
    J Clin Oncol; 1994 Sep; 12(9):1806-13. PubMed ID: 8083704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
    J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study of multiple-fraction daily radiotherapy alternating with chemotherapy in patients with stage IV non-oat cell lung cancer.
    Arcangeli G; Righini R; Nervi C; Guerra A; Tirindelli D; Hopkins H; Looney W
    Cancer Treat Rep; 1985 Jan; 69(1):25-31. PubMed ID: 2981618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of cisplatin, cyclophosphamide, vincristine, and doxorubicin for the treatment of non-small cell lung cancer.
    Lindgren D; Cadman E; Erichson R; Grann V; Sachs K
    Cancer Treat Rep; 1984 Sep; 68(9):1159-61. PubMed ID: 6090015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer.
    Messeih AA; Schweitzer JM; Lipton A; Harvey HA; Simmonds MA; Stryker JA; Ricci JA; Hoffman SL; Gottleib RJ; Dixon RH
    Cancer Treat Rep; 1987 Jan; 71(1):61-6. PubMed ID: 3024828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
    J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
    Johnson DH; Einhorn LH; Birch R; Vollmer R; Perez C; Krauss S; Omura G; Greco FA
    J Clin Oncol; 1987 Nov; 5(11):1731-8. PubMed ID: 2824707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Randomized study of cisplatin and doxorubicin with or without vincristine in non-small cell lung cancer].
    Bando H; Kinoshita S; Atagi S; Yamasaki K; Yamashita T; Fukuta K; Ogura T; Ishimi H; Nakayama T; Kimura K
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2094-9. PubMed ID: 3717956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party.
    Sculier JP; Paesmans M; Bureau G; Dabouis G; Libert P; Vandermoten G; Van Cutsem O; Berchier MC; Ries F; Michel J
    J Clin Oncol; 1993 Oct; 11(10):1858-65. PubMed ID: 8410110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin.
    Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
    Gynecol Oncol; 1997 Nov; 67(2):141-6. PubMed ID: 9367697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The benefit of cisplatin-based polychemotherapy for adenocarcinoma of the lung. The Kyushu Lung Cancer Chemotherapy Study Group.
    Hara N; Ohta M; Ichikawa Y; Kanda T; Shima K; Tamura K; Hokama M
    Cancer Chemother Pharmacol; 1990; 26(1):47-51. PubMed ID: 2108816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP) and intensive iv hyperalimentation.
    Jordan WM; Valdivieso M; Frankmann C; Gillespie M; Issell BF; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1981; 65(3-4):197-205. PubMed ID: 6786737
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer.
    Murray N; Coppin C; Coldman A; Pater J; Rapp E
    J Clin Oncol; 1994 Nov; 12(11):2333-9. PubMed ID: 7964949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.